FBN1 and myeloid sarcoma: Thus, the data reported so far reveal that in more than two-thirds of the patients with MS, missense mutations are detected, of which only 25% affect domains other than the cbEGF domains of fibrillin-1, in these patients, the cardiovascular and skeletal damage is much more severe.